



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

'NEELAM CENTRE', 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:273

December 2, 2010

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Press Release

Enclosed please find press release on US FDA approval received by the company for Diclofenac Sodium Tablets (25mg. & 50mg.).

We request you to take the above on record.

Thanking you,

Yours faithfully,
for J.B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary - General Manager



J. B. Chemicals & Pharmaceuticals Limited

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM


J.B.Chemicals receives US FDA approval for Diclofenac Sodium Tablets

Mumbai, December 02, 2010:

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) announces the receipt of US FDA Approval to its Abbreviated New Drug Application (ANDA) for 25 mg. and 50 mg. delayed release tablets of Diclofenac Sodium (Non-Steroidal Anti-inflammatory Drug).

JBCPL already markets 75 mg. delayed release tablets of Diclofenac Sodium in US market. With this new approval received, JBCPL now has full range of Diclofenac Sodium formulations to offer in US market. This new approval will help increase the existing business of 75 mg tablets of this product. As the company has established partners in US for this product, the company expects to commercialize this approval in Q4 this year. The estimated market in US for Diclofenac Sodium formulations is US \$ 400 million.

The company manufactures the API Diclofenac Sodium itself that will help achieve better margins. With approval of Diclofenac Sodium formulations by US FDA and the company having US Drug Master file and Certificate of Suitability from EU for the API Diclofenac Sodium, the company now is poised to become significant generic player in the business of this product in US market.



About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMFs and ANDAs. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.

